Inhibrx Biosciences, Inc.

0 products tracked · names used in filings: Inhibrx Biosciences, Inc.

Upcoming milestones

Wed 14 Apr 2027🇺🇸 PDUFA datecompany-announcedin 151 days

ozekibart (INBRX-109): PDUFA target action date (conventional chondrosarcoma)

Inhibrx Biosciences, Inc. (INBX); ozekibart; BLA; status: set; "Food and Drug Administration (FDA) accepted for filing the Company’s biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027."; filed 2026-08-13 · source

Recent milestones

No recent milestones.

Products

No products recorded.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.